ELAC2 Gene Prostate Cancer Hereditary Type 2 Susceptibility to Genetic Test
Welcome to DNA Labs UAE, where we offer the ELAC2 Gene Prostate Cancer Hereditary Type 2 Susceptibility to Genetic Test. This test can help determine an individual’s susceptibility to hereditary type 2 prostate cancer and provide important information for personalized treatment and screening recommendations.
Test Details
The ELAC2 gene is a gene that encodes the enzyme RNase Z, which is involved in the processing of transfer RNA (tRNA) molecules. Mutations in the ELAC2 gene have been associated with an increased risk of developing prostate cancer, particularly hereditary type 2 prostate cancer.
NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the simultaneous analysis of multiple genes or even the entire genome. It can identify mutations or variations in the ELAC2 gene and other genes associated with prostate cancer.
Test Components
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Cancer
- Doctor: Oncologist
- Test Department: Genetics
Pre Test Information
Before undergoing the ELAC2 Gene Prostate Cancer Hereditary Type 2 Susceptibility to Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected with ELAC2 Gene Prostate Cancer, hereditary type 2, susceptibility to NGS Genetic DNA Test gene ELAC2.
Please note that genetic testing for prostate cancer susceptibility is typically recommended for individuals with a family history of the disease or those who meet certain clinical criteria. A genetic counselor or healthcare provider can help determine if NGS genetic testing for ELAC2 and other genes associated with prostate cancer is appropriate for an individual.
For more information or to schedule a test, please contact our Genetics Test Department.
Test Name | ELAC2 Gene Prostate cancer hereditary type 2 susceptibility to Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Cancer |
Doctor | Oncologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for ELAC2 Gene Prostate cancer, hereditary type 2, susceptibility to NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ELAC2 Gene Prostate cancer, hereditary type 2, susceptibility to NGS Genetic DNA Test gene ELAC2 |
Test Details |
The ELAC2 gene is a gene that encodes the enzyme RNase Z, which is involved in the processing of transfer RNA (tRNA) molecules. Mutations in the ELAC2 gene have been associated with an increased risk of developing prostate cancer, particularly hereditary type 2 prostate cancer. NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the simultaneous analysis of multiple genes or even the entire genome. It can identify mutations or variations in the ELAC2 gene and other genes associated with prostate cancer. This type of testing can help determine an individual’s susceptibility to hereditary type 2 prostate cancer and provide important information for personalized treatment and screening recommendations. It is important to note that genetic testing for prostate cancer susceptibility is typically recommended for individuals with a family history of the disease or those who meet certain clinical criteria. A genetic counselor or healthcare provider can help determine if NGS genetic testing for ELAC2 and other genes associated with prostate cancer is appropriate for an individual. |